Rubicon Research (RUBICON) Q1 25/26 earnings summary

Executive summary

• Consolidated interim financials prepared for inclusion in IPO documents, covering the three months ended June 30, 2024.

• Group operates across the pharmaceutical value chain, with global subsidiaries and recent acquisition of Validus Pharmaceuticals LLC in the US.

Financial highlights

• Revenue from operations for the quarter was ₹3,167.19 million, with total revenue at ₹3,219.00 million.

• Net profit attributable to owners was ₹255.65 million; total comprehensive income was ₹239.35 million.

• EBITDA and EBIT not explicitly stated, but operating profit before tax was ₹411.56 million.

• Basic and diluted EPS for the period were ₹1.68 and ₹1.65, respectively.

• Cash and cash equivalents at period end were ₹794.78 million.

Outlook and guidance

• Financials prepared for IPO purposes; no explicit forward-looking guidance provided.